IL2 and cancer: Clinically available compounds performing such functions led to accelerated clearance of Yersinia pestis and repair of inflamed tissue in non-human primates (115), and co-administration of Vγ9Vδ2 T cell agonists and IL-2 in cancer patients induced efficient activation of γδ T cells, and ultimately disease stabilization (116, 117).